Emergent Biosolutions Inc. (EBS): Daniel Abdun-nabi , President & CEO of Emergent Biosolutions Inc. sold 8,701 shares on May 20, 2016. The Insider selling transaction was reported by the company on May 24, 2016 to the Securities and Exchange Commission. The shares were sold at $42.00 per share for a total value of $365,442.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 24, 2016, Jerome M Hauer (director) sold 3,134 shares at $41.22 per share price.On May 16, 2016, Louis W Sullivan (director) sold 47,631 shares at $39.12 per share price.Also, On May 13, 2016, Fuad El-hibri (Chairman) sold 25,000 shares at $38.71 per share price.On Apr 20, 2016, Daniel Abdun-nabi (President & CEO) sold 8,702 shares at $40.17 per share price.
Emergent Biosolutions Inc: On Friday, May 20, 2016 heightened volatility was witnessed in Emergent Biosolutions Inc which led to swings in the share price. The shares opened for trading at $41.49 and hit $42.26 on the upside , eventually ending the session at $42.07, with a gain of 2.01% or 0.83 points. The heightened volatility saw the trading volume jump to 3,86,362 shares. The 52-week high of the share price is $42.26 and the company has a market cap of $1,685 M . The 52-week low of the share price is at $27.68.
Company has been under the radar of several Street Analysts.Emergent Biosolutions Inc is Initiated by Chardan Capital Markets to Buy and the brokerage firm has set the Price Target at $47. The Rating was issued on Apr 15, 2016.Emergent Biosolutions Inc is Initiated by Singular Research to Buy and the brokerage firm has set the Price Target at $44. The Rating was issued on Mar 28, 2016.
Emergent BioSolutions Inc. is a biopharmaceutical company that offers specialized products to healthcare providers and Governments to address medical needs and emerging health threats. The Company’s two operating divisions include Biodefense and Biosciences. The Company’s Biodefense division is a pharmaceutical business focused on countermeasures that address CBRNE (Chemical Biological Radiological Nuclear and Explosives) threats. The Biodefense division’s marketed products are BioThrax; BAT; Anthrasil; VIGIV and RSDL. The Biodefense division investigational stage product candidates include NuThrax PreviThrax GC-072 and other biodefense product candidates. The Biosciences division’s marketed products are WinRho SDF HepaGam B VARIZIG and episil. The Biosciences division investigational stage product candidates include IXINITY ES414 and otlertuzumab.